Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Continuation in Rheumatoid Arthritis
NCT00583557Phase 2Terminated
- Sponsor
- Human Genome Sciences
- Start
- Jan 2005
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of belimumab in rheumatoid arthritis (RA), sponsored by Human Genome Sciences. Primary endpoint: Long-term Safety at 5 years. Started Jan 2005; status: terminated.
02
Drugs
belimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00583557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583557.